EMA Reorganizes
EMA restructures organization.
RELATED ARTICLES
The European Medicines Agency is moving forward with plans to restructure the organization. EMA’s management team began transitioning to a new structure on August 1, 2013. The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.
EMA will announce details of the new structure of the organization in September 2013.
Source: European Medicines Agency
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/08/news_detail_001868.jsp&mid=WC0b01ac058004d5c1
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
